Inventor · disambiguated record
Karla A. Henning
Also filed as: HENNING KARLA · HENNING KARLA A · HENNING KARLA ANN
22 granted patents·16 pending applications·235 citations·filing 2002–2025
95Inventor score
Files withBRISTOL MYERS SQUIBB CO27BOLT BIOTHERAPEUTICS INC5PFIZER4BRISTOL MAYERS SQUIBB COMPANY1CORIXA CORP1
Top patents by PatentIndex Score
38 records- 0198US9228016B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 5, 2016·85 cites·19 claims
- 0297US10501550B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 10, 2019·9 cites·58 claims
- 0397US10465010B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Nov 5, 2019·9 cites·15 claims
- 0497US9745379B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Aug 29, 2017·11 cites·58 claims
- 0597US9605080B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 28, 2017·31 cites·30 claims
- 0696US10100129B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 16, 2018·24 cites·35 claims
- 0794US11084881B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Aug 10, 2021·3 cites·19 claims
- 0893US11213586B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 4, 2022·5 cites·14 claims
- 0993US9683998B2Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereofPFIZER·Filed 2014·Granted Jun 20, 2017·32 cites·13 claims
- 1092US10690674B2Anti-GITR antibodies for cancer diagnosticsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 23, 2020·5 cites·27 claims
- 1191US10653791B2Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 19, 2020·10 cites·6 claims
- 1290US12077584B2Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)BRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 3, 2024·1 cites·76 claims
- 1390US11474112B2Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereofPFIZER·Filed 2019·Granted Oct 18, 2022·4 cites·27 claims
- 1490US10167343B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 1, 2019·3 cites·34 claims
- 1588US11274150B2Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodiesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 15, 2022·2 cites·113 claims
- 1688US2024158524A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 1784US11408889B2Anti-GITR antibodies for cancer diagnosticsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Aug 9, 2022·1 cites·20 claims
- 1883US2025101100A1Anti-nkg2a antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1980US2023051701A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2079US12372536B2Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereofPFIZER·Filed 2022·Granted Jul 29, 2025·0 cites·30 claims
- 2179US12325750B2Anti-Dectin-2 antibodies and methods of usingBOLT BIOTHERAPEUTICS INC·Filed 2023·Granted Jun 10, 2025·0 cites·29 claims
- 2279US2023050665A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 2378US11981734B2Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)BRISTOL MYERS SQUIBB CO·Filed 2022·Granted May 14, 2024·0 cites·163 claims
- 2477US11802162B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 31, 2023·0 cites·25 claims
- 2574US2024141059A1Antibodies comprising modified heavy constant regionsBRISTOL MAYERS SQUIBB COMPANY·Filed 2023·Application pending·0 cites
- 2673US11753474B2Anti-Dectin-2 antibodiesBOLT BIOTHERAPEUTICS INC·Filed 2022·Granted Sep 12, 2023·0 cites·131 claims
- 2773US2025270329A1Anti-Dectin-2 AntibodiesBOLT BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2872US11352440B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 7, 2022·0 cites·18 claims
- 2971US2022175921A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 3064US2019055320A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 3160US2020268901A1Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 3255US2018052175A1Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereofPFIZER·Filed 2017·Application pending·0 cites
- 3355US2020299400A1Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 3451US2023069055A1Anti-pd-l1 antibodiesBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3549US2023086603A1Anti-pd-l1 antibodiesBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3646US2004161817A1Compositions and methods for high-level, large-scale production of recombinant proteinsCORIXA CORP·Filed 2002·Application pending·0 cites
- 3742US2017326249A1Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and usesBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 3838US2019284293A1Combination therapy with anti-cd73 antibodiesBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →